Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma

References

• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Zelenetz A, Schoder H. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw 2010;8:347–352.
   PubMed Web of Science ®Google Scholar
• Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 2010;51:1857–1862.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Meignan M, et al. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009;50:1257–1260.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Haioun C, et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 2010;51:2171–2180.
   PubMed Web of Science ®Google Scholar
• Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48: 1626–1632.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2004;22:2826–2834.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010;115:775–777; quiz 918.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011;118:37–43.
   PubMed Web of Science ®Google Scholar
• Michallet AS, Trotman J, Tychyj-Pinel C. Role of early PET in the management of diffuse large B-cell lymphoma. Curr Opin Oncol 2010;22:414–418.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma 2010;51(Suppl. 1):28–33.
   PubMed Web of Science ®Google Scholar
• Huttmann A, Muller S, Jockel KH, et al. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. J Clin Oncol 2010;28:e488–e489; author reply e490–e481.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Smith B, Itti E, et al. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma?. J Clin Oncol 2010;28:e719–e720; author reply e721–e712.
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613–618.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Timothy AR, O’Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543–553.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356–1363.
   PubMed Web of Science ®Google Scholar
• Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43:1018–1027.
   PubMed Web of Science ®Google Scholar
• Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527–533.
   PubMed Web of Science ®Google Scholar
• Haioun C, Itti E, Rahmouni A, et al[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
   PubMed Web of Science ®Google Scholar
• Yang DH, Min JJ, Song HC, et al. Prognostic significance of interim 18F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer 2011; 47:1312–1318.
   PubMed Web of Science ®Google Scholar
• Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012;30:184–190.
   PubMed Web of Science ®Google Scholar
• Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119: 2066–2073.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–1903.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2012:397–401.
   Google Scholar
• Terasawa T, Nagai H. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes. Leuk Lymphoma 2009;50:1750–1752.
   PubMed Web of Science ®Google Scholar
• Meignan M. Interim PET in lymphoma: a step towards standardization. Eur J Nucl Med Mol Imaging 2010;37:1821–1823.
   PubMed Web of Science ®Google Scholar
• Cashen AF, Dehdashti F, Luo J, et al. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011;52:386–392.
   PubMed Web of Science ®Google Scholar
• Yoo C, Lee DH, Kim JE, et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011;90:797–802.
   PubMed Web of Science ®Google Scholar
• Han HS, Escalon MP, Hsiao B, et al. High incidence of false- positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20:309–318.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant 2009;15:242–248.
   PubMed Web of Science ®Google Scholar
• Casasnovas R-O, Sasanelli M, Berriolo-Riedinger A, et al. Baseline metabolic tumor volume is predictive of patient outcome in diffuse large B cell lymphoma. Blood 2012;120(Suppl. 1): Abstract 1598.
   PubMed Web of Science ®Google Scholar
• Fields PA, Mikhaeel G, Hutchings M, et al. The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. Haematologica 2005;90:1711–1713.
   PubMed Web of Science ®Google Scholar
• De Paepe K, Bevernage C, De Keyzer F, et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging 2013;13:53–62.
   PubMed Web of Science ®Google Scholar